Rescuing the last-line polymyxins: achievements and challenges

SC Nang, MAK Azad, T Velkov, QT Zhou, J Li… - Pharmacological …, 2021 - Elsevier
Antibiotic resistance is a major global health challenge and, worryingly, several key Gram
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …

Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae

J Rodríguez-Baño, B Gutiérrez-Gutiérrez… - Clinical microbiology …, 2018 - Am Soc Microbiol
Therapy of invasive infections due to multidrug-resistant Enterobacteriaceae (MDR-E) is
challenging, and some of the few active drugs are not available in many countries. For …

Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods

CR Lee, JH Lee, KS Park, YB Kim, BC Jeong… - Frontiers in …, 2016 - frontiersin.org
The emergence of carbapenem-resistant Gram-negative pathogens poses a serious threat
to public health worldwide. In particular, the increasing prevalence of carbapenem-resistant …

The rapid spread of carbapenem-resistant Enterobacteriaceae

RF Potter, AW D'Souza, G Dantas - Drug Resistance Updates, 2016 - Elsevier
Carbapenems, our one-time silver bullet for multidrug resistant bacterial infections, are now
threatened by widespread dissemination of carbapenem-resistant Enterobacteriaceae …

Carbapenemases: Transforming Acinetobacter baumannii into a Yet More Dangerous Menace

MS Ramirez, RA Bonomo, ME Tolmasky - Biomolecules, 2020 - mdpi.com
Acinetobacter baumannii is a common cause of serious nosocomial infections. Although
community-acquired infections are observed, the vast majority occur in people with …

[HTML][HTML] Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli

L Scudeller, E Righi, M Chiamenti, D Bragantini… - International journal of …, 2021 - Elsevier
Background: The superiority of combination therapy for carbapenem-resistant Gram-
negative bacilli (CR-GNB) remains controversial. In vitro models may predict the efficacy of …

Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?

TB Tran, T Velkov, RL Nation, A Forrest, BT Tsuji… - International journal of …, 2016 - Elsevier
The polymyxin antibiotics [colistin and polymyxin B (PMB)] are increasingly used as a last-
line option for the treatment of infections caused by extensively drug-resistant Gram …

Recent advances and perspectives in the design and development of polymyxins

F Rabanal, Y Cajal - Natural product reports, 2017 - pubs.rsc.org
Covering: 1947-early 2017, particularly from 2005-early 2017 The rise of bacterial
pathogens with acquired resistance to almost all available antibiotics is becoming a serious …

Colistin: still a lifesaver for the 21st century?

I Karaiskos, M Souli, I Galani… - Expert opinion on drug …, 2017 - Taylor & Francis
Introduction: Living in the 'era of antibiotic resistance'and facing the threat of an 'end to
antibiotics', physicians in the last decade have revived use of colistin, since the available …

Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam–epidemiology, laboratory detection and treatment …

N Sherry, B Howden - Expert review of anti-infective therapy, 2018 - Taylor & Francis
ABSTRACT Introduction: Multidrug-resistant (MDR) and extensively-drug-resistant (XDR)
Gram-negative bacteria have emerged as a major threat to human health globally. This has …